Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
1(33%)
Results Posted
100%(2 trials)

Phase Distribution

Ph phase_1
1
33%
Ph early_phase_1
1
33%
Ph not_applicable
1
33%

Phase Distribution

2

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Early Phase 1First-in-human
1(33.3%)
Phase 1Safety & dosage
1(33.3%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Completed(2)

Detailed Status

Completed2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Early Phase 1

Trials by Phase

Early Phase 11 (33.3%)
Phase 11 (33.3%)
N/A1 (33.3%)

Trials by Status

completed267%
recruiting133%

Recent Activity

1 active trials
Showing 3 of 3
recruitingnot_applicable

Coated or Chewable Aspirin and a Hybrid Strategy to Mitigate Adverse Effects of Air Pollution in Stable Atherosclerotic Disease

NCT06541691
completedphase_1

L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients

NCT02834403
completedearly_phase_1

Aspirin Resistance in Coronary Artery Disease

NCT00753935

Clinical Trials (3)

Showing 3 of 3 trials
NCT06541691Not Applicable

Coated or Chewable Aspirin and a Hybrid Strategy to Mitigate Adverse Effects of Air Pollution in Stable Atherosclerotic Disease

Recruiting
NCT02834403Phase 1

L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients

Completed
NCT00753935Early Phase 1

Aspirin Resistance in Coronary Artery Disease

Completed

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3